Abstract
Our aim was to determine the sensitivity andspecificity of p53 accumulation as a marker of malignantpotential in Barrett's metaplasia (BM). One hundredeighty biopsies from 61 patients with BM were evaluated for p53 accumulation by immunohistochemistry.Of 25 patients with LGD, 9 had p53-positive biopsies,and of these 5 (56%) developed HGD/CA, whereas 16 hadp53-negative biopsies and none (0%) developed HGD/CA after similar follow-up times (P = 0.0108). Asa marker of malignant potential in BM, p53 accumulationhas a sensitivity of 100%, specificity of 93%, and apredictive value of a positive test of 0.56, compared to sensitivity of 100%, specificity of 64%, andpredictive value of a positive test of 0.2 for ahistologic diagnosis of LGD. We conclude that: (1) p53accumulation is more specific and has better predictive value for subsequent development of HGD/CA thanhistologic diagnosis of LGD. (2) Patients with LGD andp53-positive biopsies are more likely to develop HGD/CA;therefore, they should be followed up more closely than those with LGD and p53-negativebiopsies.
Similar content being viewed by others
REFERENCES
Phillips RW, Wong RKH: Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 20:791–816, 1991
Haggitt RC, Tryzelaar J, Ellis H, Colcher H: Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 70:1–5, 1978
Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR: Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 198:554–566, 1983
Naef AP, Savary M, Ozzello L, Pearson FG: Columnar-lined lower esophagus. An acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. Ann Thorac Surg 13:543–551, 1972
Young JR Jr, Percy CL, Asire AJ: Surveillance, epidemiology, and end results: Incidence and mortality data 1973–1977. Monogr Natl Cancer Inst 57:140–141, 1981
Bolt WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289, 1991
Bolt WJ, Devesa SS, Fraumeni JF Jr: Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA 270:1320, 1993
Steritz JM, Ellis FH, Gibb SP, Balogh K, Watkins E: Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases. Ann Surg 213:122–125, 1991
Paraf F, Flejou J-F, Pignon J-P, Fekete F, Potet F: Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol 19:183–191, 1995
Miros M, Kerlin P, Walker N: Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 32:1441–1446, 1991
Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, Den Besten L, Rubin CE: Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94:81–90, 1988
Tytgat GNJ, Hameeteman W: The neoplastic potential of columnar-lined (Barrett's) esophagus. World J Surg 16:308–312, 1992
Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, MacDonald W, Owen D: Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19:166–178, 1988
Achkar E, Carey WC: The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 83:291–294, 1988
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumor antigen to band 17p13. Nature 320:84–85, 1986
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, VanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221, 1989
Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacran-fixed, embedded tissue. Am J Pathol 140:145–153, 1992
Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ 1:571–580, 1990
Hamelin R, Flejou J-F, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107:1012–1018, 1994
Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, Rabinovitch PS, Reid BJ: 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 51:5482–5486, 1991
Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, Haggitt RC, Dean PJ, Thor K, Rabinovitch P: Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 102:1220–1228, 1992
Symmans PJ, Linehan JM, Brito MJ, Filipe ME: p53 expression in Barrett's esophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 173:221–226, 1994
Hardwick RH, Shephard NA, Moorghen M, Newcomb PV, Alderson D: Adenocarcinoma arising in Barrett's oesophagus: Evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 35:764–768, 1994
Younes M, Lebovitz R, Lechago LV, Lechago J: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study. Gastroenterology 105:1637–1642, 1993
Haggitt RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982–993, 1994
Dawson-Saunders B, Trapp RG: Evaluating diagnostic procedures. In Basic and Clinical Biostatistics. B Dawson-Saunders, RG Trapp (eds). Norwalk, Appelton and Lange, 1990, pp 229–244
Younes M, Riley S, Genta R, Mosharaf M, Mody D: p53 protein accumulation in tumors of the ampulla of Vater. Cancer 76:1150–1154, 1995
Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol 144:511–517, 1994
Rodriguez NA, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555–7559, 1990
Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899, 1990
Rights and permissions
About this article
Cite this article
Younes, M., Ertan, A., Lechago, L.V. et al. p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia. Dig Dis Sci 42, 697–701 (1997). https://doi.org/10.1023/A:1018828207371
Issue Date:
DOI: https://doi.org/10.1023/A:1018828207371